Verteporfin (Visudyne), a photosensitizer approved for macular degeneration treatment, was the first molecule developed and was shown to inhibit YAP1/TEAD interactions, diminishing YAP1 signaling [81]. This evidence concerns the gene YAP1 and macular degeneration.